Thanks Doc. There is Direct too. Absolutely. I enjoy reading your posts about this, and this is what I gather.
The original tumor’s defense against the immune response is its hypoxic (low oxygen) environment. Dendritic cells are paralyzed by the tumor. T cells, B cells, and Dendritic cells cannot stay in the tumor long enough to complete its normal full immune process. If immune cells do not stay, that becomes the place where the initial battle is lost and where the cancer can stay to grow unchecked. That leads us back to why we desperately need: DCVax-L + CI + Poly ICLC + CSF -1R inhibitor.
I think what you are also saying too is that if the normal immune response has a chance to fully process and complete, meaning it has time to form a systemic immune defense shield of memory T cells and B cells to guard against rogue cancer cells metastasizing and cancer recurrence, then the cancer can be controlled or killed right off the bat, just like when we catch a cold, recover, and become immune.
That normal immune process or response refers to having enough completed cycles of: DCs pick up antigens inside tumor, go to lymph nodes, inform T cells and B cells, cells reproduce/multiply, go to fight, become exhausted, apoptosis or become memory cells, rinse and repeat back to DCs.
Your point being that DCVax-Direct is different altogether. It goes back to the initial battle lost, inside the tumor, and completes the normal immune process where the immune system originally lost.
How? Because DCVax-Direct is a tumor microenvironment modulator. It is injected directly into the tumor and releases the pro-inflammatory cytokines (tnf alpha, IL6 and IL8). These modulate the environment, so the tumor becomes immune supportive rather than immune suppressive. This allows DCs to spend time inside the tumor, picking up antigens, further maturing, expressing more cytokines to modulate against immune suppression defenses by the tumor, and to complete the immune process.
It makes sense. Direct is about being injected into multiple non-operable tumors to get a sufficient diversity of antigen specific memory T cell and B cells. It is also about the proper spacing of treatments to ensure there is enough repeat cycles.
I am actually very excited about DCVax-Direct being a next generation after DCVax-L and look forward to learning more of Direct as more information comes out down the road.
Bullish
News 
Market Data 
Discover 
AI
